Del Giudice and colleagues (2015), Current Topics in Medicinal Chemistry. Labelled a phase II clinical trial; sample size not stated in the abstract. Reports cytokine reductions and outcomes the authors call comparable to narrow-band UVB, using a “WHITE Holographic Bioresonance” method.
Category Archives: Independent
Carried out by a university, hospital or research institute with no commercial link to a bioresonance device manufacturer, and published outside the bioresonance community.
Genç and colleagues (2024), Anadolu Tıbbı Dergisi, Turkish. Case report, two patients in breast cancer follow-up. Reports SF-36 quality of life improvement after one month of BICOM Optima sessions. Two cases, no comparison group.
Barassi and colleagues (2024), Medicina (Kaunas). Pilot observational study, before and after, 20 patients. Reports changes in SF-36, Bristol stool scale and faecal calprotectin after eight sessions. The device is an extremely low frequency electromagnetic field system, not BICOM or MORA.
Dur and Şensoy (2026), International Journal of Traditional and Complementary Medicine Research. Prospective single-arm cohort, 50 smokers, carbon monoxide verified at one and three months. Reports 28 per cent continuous abstinence at twelve months; low mood and sleep problems predicted relapse.
Marakoğlu and colleagues (2024), İstanbul Medical Journal. Retrospective cohort from a smoking cessation clinic, 1,272 patients. Reports MORA bioresonance was the most chosen method, and no significant difference in quit success between methods (p=0.132).
Muresan and colleagues (2022), Experimental and Therapeutic Medicine. Two-group comparison against SSRI monotherapy, not randomised. Reports mean Hamilton score change of 3.1 with bioresonance against 2.2 with SSRI. Overlaps the group’s 2021 dataset.
Muresan and colleagues (2021), Journal of Interdisciplinary Medicine. Single arm, before and after, 40 patients. Reports a fall in Hamilton depression score after five weeks. Likely the same cohort as the group’s Journal of Medicine and Life paper.
Muresan and colleagues (2021), Journal of Medicine and Life. Three groups, not randomised: bioresonance alone, bioresonance plus antidepressant, antidepressant alone, 140 patients. Reports HAM-D reductions of 3.1, 3.8 and 2.3 points after five weeks. MORA Nova device.
Badtieva and colleagues (2018), Voprosy Kurortologii. Controlled trial with a sham (non-functioning) device, 60 athletes, Russian. Reports improvement in clinical and instrumental measures against the sham group.
Kiryanova and colleagues (2017), Kazan Medical Journal. Three-group comparison (treatment, control, placebo), 413 patients, Russian. Reports lower HbA1c, glucose and BMI at three months in the bioresonance group.